Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retching

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Retching. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-002947-23 Sponsor Protocol Number: DP10027 Start Date*: 2023-04-14
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients
    Medical condition: post-operative nausea and vomiting in pediatric patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002180-24 Sponsor Protocol Number: 2004An0007 Start Date*: 2005-04-12
    Sponsor Name:Swindon & Marlborough NHS Trust
    Full Title: Prospective randomised double blind comparative study of cinnarizine versus placebo as prophylactic anti-travel sickness therapy in patients undergoing dy-case gynaecological surgery.
    Medical condition: Post operative nausea and vomiting and motion sickness
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001021-22 Sponsor Protocol Number: NKO101287 Start Date*: 2005-02-08
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-000370-31 Sponsor Protocol Number: NKT102260 Start Date*: 2005-05-20
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Ant...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005803-33 Sponsor Protocol Number: TH06-001 Start Date*: 2007-01-18
    Sponsor Name:THERABEL LUCIEN PHARMA
    Full Title: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE...
    Medical condition: The prevention of acute or delayed Chemotherapy-Induced Nausea and Vomiting (CINV) by the combination of palonosetron 250 microgrammes and methylprednisolone 80 mg in patients receiving a first adm...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001491-13 Sponsor Protocol Number: CPP-01/04N Start Date*: 2005-09-01
    Sponsor Name:Combustin Pharmazeutische Präparate GmbH
    Full Title: Klinische Prüfung von Acoin im Vergleich zu Tetracain bei Patienten, die sich einer Bronchoskopie unterziehen müssen (Clinical trial with Acoin as compared with tetracaine in patients who have to u...
    Medical condition: Patients who have to undergo bronchoscopy for diagnostic reasons, ie ICD classification cannot be stated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003992-30 Sponsor Protocol Number: DP10019 Start Date*: 2016-03-08
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had prior prophylaxis
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002041-59 Sponsor Protocol Number: DP10018 Start Date*: 2015-09-11
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had no prior prophyl...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017800-10 Sponsor Protocol Number: CZB/4/722 Start Date*: 2010-04-01
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. University of Edinburgh
    Full Title: Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP)
    Medical condition: Paracetamol overdose
    Disease: Version SOC Term Classification Code Term Level
    2.2 10033295 Overdose LLT
    2.2 10033297 accidental overdose LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002594-33 Sponsor Protocol Number: TZP-102-CL-G003 Start Date*: 2011-10-14
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated w...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002576-14 Sponsor Protocol Number: TZP-102-CL-G004 Start Date*: 2012-08-23
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associate...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004267-71 Sponsor Protocol Number: DP10006 Start Date*: 2011-12-12
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomiting
    Medical condition: Post-operative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003206-41 Sponsor Protocol Number: TAK-954-2002 Start Date*: 2018-05-29
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Int...
    Medical condition: A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Int...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10074293 Enteral feeding intolerance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005856-42 Sponsor Protocol Number: NKT102553 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Preventi...
    Medical condition: Postoperative Nausea and Vomiting (PONV)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000369-37 Sponsor Protocol Number: NKT102245 Start Date*: 2005-02-01
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005855-16 Sponsor Protocol Number: NKT102552 Start Date*: 2006-03-20
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for...
    Medical condition: Postoperative Nausea and Vomiting (PONV)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) ES (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004712-73 Sponsor Protocol Number: P04351 Start Date*: 2006-08-31
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomi...
    Medical condition: Chemotherapy Induced Nausea and Vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005003-41 Sponsor Protocol Number: 392MD/15/C Start Date*: Information not available in EudraCT
    Sponsor Name:Strakan Pharmaceuticals Ltd
    Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000781-37 Sponsor Protocol Number: NKV102549 Start Date*: 2006-07-24
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005169-36 Sponsor Protocol Number: NKV110721 Start Date*: 2008-02-07
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: NKV110721, A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting
    Medical condition: Prevention of nausea and vomiting due to first cycle of oxaliplatin based chemotherapy in patients with colorectal cancer receiving a combination with 5-fluorouracil and leucovorin, or in combinati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 16:12:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA